Antibacterial research and development in the 21 st Century - An industry perspective of the challenges

Current Opinion in Microbiology

Volumn 7, Issue 5, 2004, Pages 445-450

  Thomson, Christopher J ^a   Power, Edward ^b   Ruebsamen Waigmann, Helga ^c   Labischinski, Harald ^c  

^a Bayer plc UK   (United Kingdom)

^b BAYER CORPORATION   (United States)

^c BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 AMINO 3,5 DIFLUORO 2 PYRIDYL) 8 CHLORO 6 FLUORO 1,4 DIHYDRO 7 (3 HYDROXY 1 AZETIDINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; ANTIINFECTIVE AGENT; BAY 73 7388; BETA LACTAM; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CS 023; DALBAVANCIN; DAPTOMYCIN; DORIPENEM; FOLIC ACID ANTAGONIST; GARENOXACIN; GLYCOPEPTIDE; ICLAPRIM; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; BIOINFORMATICS; BIOTECHNOLOGY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG INDUSTRY; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; DRUG TARGETING; GENE SEQUENCE; GENOMICS; HUMAN; INFECTION CONTROL; INFRARED SPECTROSCOPY; KNOCKOUT GENE; MEDICAL RESEARCH; PATHOGENICITY; PHARMACOPHORE; PHENOTYPE; PHYSICAL CHEMISTRY; PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS; REVIEW; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG RESISTANCE, BACTERIAL; HUMANS; RESEARCH;

BACTERIA (MICROORGANISMS);

EID: 4644242447     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2004.08.009     Document Type: Review

References (44)

1. D.M. Livermore Bacterial resistance: origins, epidemiology, and impact Clin Infect Dis 36 supp1 2003 S11 S23
2. A. Coates, Y. Hu, R. Bax, and C. Page The future challenges facing the development of new Antimicrobial drugs Nat Rev Drug Discov 1 2002 895 910
3. D. McDevitt, and M. Rosenberg Exploiting genomics to discover new antibiotics Trends Microbiol 9 2001 611 617
4. B. Spellberg, J.H. Powers, E.P. Brass, L.G. Miller, and J.E. Edwards Trends in Antimicrobial Drug Development: Implications for the Future Clin Infect Dis 38 2004 1279 1286 Excellent description of the most important current challenges in antibacterial RandD including proposal how to overcome those from an infectious disease specialist point of view.
5. H. Labischinski New Antibiotics Int J Med Microbiol 291 2001 317 318
6. D. Abbanat, M. Macielag, and K. Bush Novel antibacterial agents for the treatment of serious Gram-positive infections Expert Opin Investig Drugs 12 2003 379 399 Detailed and accurate description of the current antibiotic pipeline of gram-positive agents.
7. J.A. Dimasi, R.W. Hansen, and H.G. Grabowski The price of innovation: new estimates of drug development costs J Health Econ 22 2003 325 330 Based on thorough economical studies, drug development costs in the pharmaceutical sector are analysed including estimates of attrition rates and comparisons of different therapy areas.
8. K. Poole Overcoming multidrug resistance in Gram-negative bacteria Curr Opin Investig Drugs 4 2003 128 139
9. S. Bronzwaer, A. Lonnroth, and R. Haigh The European Community strategy against antimicrobial resistance Euro Surveill 9 2004 1 3
10. WHO: WHO global strategy for containment of microbial resistance. 2001 (http://www.who.int/csr/resources/publications/drugresist/EGlobalStrat.pdf).
11. R. Bax How to evaluate and predict the ecological impact of antibiotics: the pharmaceutical industry view from research and development Clin Microbiol Infect 7 s5 2001 46 48
12. S.J. Projan Why is Big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6 2003 427 430 Excellent discussion on the factors influencing strategic decisions concerning maintaining an in house antibacterial research and development capability within pharmaceutical companies.
13. C.T. Barrett, and J.F. Barret Antibacterials: are the new entries enough to deal with the emerging resistance problems? Curr Opin Biotechnol 14 2003 621 625
14. D.M. Shlaes, and R.C. Moellering The United States Food and Drug administration and the end of antibiotics Clin Infect Dis 34 2002 420 422
15. G.L. Drusano Antimicrobial pharmacodynamics: critical interactions of "bug and drug" Nat Rev Microbiol 2 2004 289 300
16. J.H. Powers Development of drugs for antimicrobial-resistant pathogens Curr Opin Infect Dis 16 2003 547 551 Good overview of the critical issues and current thinking of regulatory bodies on how to incentivise antibacterial drug research and development in areas where the medical need is high.
17. I. Chopra, L. Hesse, and A.J. O'Neill Exploiting current understanding of antibiotic action for discovery of new drugs J Appl Microbiol 92 2002 4S 15S
18. R.D. Fleischmann, M.D. Adams, O. White, R.A. Clayton, E.F. Kirkness, A.R. Kerlavage, C.J. Bult, J.F. Tomb, B.A. Dougherty, and J.M. Merrick Whole-genome random sequencing and assembly of Haemophilus influenzae Rd Science 269 1995 496 512
19. http://www.tigr.org/tigr-scripts/CMR2/CMRGenomes.spl.
20. C. Freiberg, and N.A. Brunner Genome-wide mRNA profiling: impact on compound evaluation and target identification in anti-bacterial research Targets 1 2002 20 29
21. Freiberg C, Broetz-Oesterhelt H, Labischinski H: The impact of transcriptome and proteome analysis on antibacterial drug discovery. Curr Opin Microbiol 2004, in press.
22. J.E. Bandow, H. Brotz, L.I. Leichert, H. Labischinski, and M. Hecker Proteomic approach to understanding antibiotic action Antimicrob Agents Chemother 47 2003 948 955
23. Brötz-Oesterhelt H, Bandow JE, Labischinski H: Bacterial proteomics and its role in antibacterial drug discovery. Mass Spec Rev 2004, in press; (DOI 10.1002/mas.20030). Detailed review on the state of the art in exploiting proteomic technologies for antibacterial drug development in general and for ultra-rapid mode of action studies in particular.
24. S.A. Haney, L.E. Alksne, P.M. Dunman, E. Murphy, and S.J. Projan Genomics in anti-infective drug discovery - getting to the endgame Curr Pharm Des 8 2002 1099 1118
25. T.J. Dougherty, J.F. Barrett, and M.J. Pucci Microbial genomics and novel antibiotic discovery: new technology to search for new drugs Curr Pharm Des 8 2002 1119 1135 Insightful overview on genomic technologies currently in use in antibacterial drug research.
26. M. Hecker A proteomic view of cell physiology of Bacillus subtilis-bringing the genome sequence to life Adv Biochem Eng Biotechnol 83 2003 57 92
27. L.E. Alksne, and S.J. Projan Bacterial virulence as a target for antimicrobial therapy Curr Opin Biotechnol 11 2000 625 636
28. S. Donadio, L. Carrano, L. Brandi, S. Serina, A. Soffientini, E. Raimondi, N. Montanini, M. Sosio, and C. Gualerzi Targets and assays for discovering novel antibacterial agents J Biotechnol 99 2002 175 185
29. C.G. Lerner, and B.A. Beutel Antibacterial drug discovery in the post-genomic era Curr Drug Targets Infect Disord 2 2002 109 119
30. D.J. Payne The potential of bacterial fatty acid biosynthetic enzymes as a source of novel antibacterial agents Drug News Perspect 17 2004 187 194 This review on a target area of great interest to many pharmaceutical companies illustrates not only the potential of many, nowadays classical target driven approaches, but also demonstrates many of their previously not often recognized pitfalls e.g. target conservation in different species.
31. N.N. Kaderbhai, D.I. Broadhurst, D.I. Ellis, R. Goodacre, and D.B. Kell Functional genomics via metabolic footprinting: monitoring metabolite secretion by E. coli tryptophan metabolism mutants using FT-IR and direct injection electrospray mass spectrometry Comp Funct Genomics 4 2003 376 391
32. I. Artsimovich, C. Chu, A.S. Lynch, and R. Landick A new class of bacterial RNA polymerase inhibitors affect nucleotide addition Science 302 2003 650 653
33. +-dependent DNA ligase by pyridochromanones J Biol Chem 278 2003 39435 39442
34. D. Beyer, H.P. Kroll, R. Endermann, G. Schiffer, S. Siegel, M. Bauser, J. Pohlmann, M. Brands, K. Ziegelbauer, and D. Haebich New class of bacterial phenylalanyl-tRNA synthetase inhibitors with high potency and broad-spectrum activity Antimicrob Agents Chemother 48 2004 525 532
35. P.J. Dandliker, S.D. Pratt, A.M. Nilius, C. Black-Schaefer, X. Ruan, D.L. Towne, R.F. Clark, E.E. Englund, R. Wagner, and M. Weitzberg Novel antibacterial class Antimicrob Agents Chemother 47 2003 3831 3839 Unexpected finding of novel quinolone structures with no gyrase inhibitory activity but potent action within the protein biosynthesis target area.
36. A.E. Choudry, T.L. Mandichak, J.P. Broskey, R.W. Egolf, C. Kinsland, T.P. Begley, M.A. Seefeld, T.W. Ku, J.R. Brown, M. Zalacain, and K. Ratnam Inhibitors pf pantothenate kinase: novel antibiotics for staphylococcal infection Antimicrob Agents Chemother 47 2003 2051 2055
37. D. Chen, C. Hackbarth, Z.J. Ni, C. Wu, W. Wang, R. Jain, Y. He, K. Bracken, B. Weidmann, and D.V. Patel Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach Antimicrob Agents Chemother 48 2004 250 261
38. M. Gross, R. Bürli, P. Jones, M. Garcia, B. Batiste, J. Kaizerman, H. Moses, V. Jiang, U. Hoch, and J.X. Duan Pharmacology of novel heteroaromatic polycycle antibacterials Antimicrob Agents Chemother 47 2003 3448 3457
39. D.J. Payne, W.H. Miller, V. Berry, J. Brosky, W.J. Burgess, E. Chen, W.E. DeWolf Jr., A.P. Fosberry, R. Greenwood, and M.S. Head Discovery of a novel and potent class of FabI-directed antibacterial agents Antimicrob Agents Chemother 46 2002 3118 3124
40. 3-hydroxybutyl 6-(3′-ethyl-4′-methylanilino) uracil Antimicrob Agents Chemother 46 2002 3770 3775
41. E. Azoulay-Dupuis, J. Mohler, and J.P. Bedros Efficacy of BB-83698, a novel peptide deformylase inhibitor in a mouse model of pneumococcal pneumoniae Antimicrob Agents Chemother 48 2004 80 85
42. A. Ruzin, G. Singh, A. Severin, Y. Yang, R.G. Dushin, A.G. Sutherland, A. Minnick, M. Greenstein, M.K. May, D.M. Shlaes, and P.A. Bradford Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant gram-positive bacteria Antimicrob Agents Chemother 48 2004 728 738
43. J.A. Dimasi The value of improving the productivity of the drug development process: faster times and better decisions Pharmacoeconomics 20 Suppl 3 2002 1 10 An important and detailed analysis of factors important for success in industrial RandD. Especially important is the result that success rates in anti-infective (antibacterial as well as antiviral) development are higher than in all other therapy areas studied.
44. IDSA Report: Bad Bugs, No Drugs As Antibiotic Discovery Stagnates, A Public Health Crisis Brews; July 2004.